Brisbane—It’s May 4, 2026, clock just past 8:03 AEST.
ALS Ltd is just two weeks out from its FY26 results briefing, with investors watching to see if the Australian testing group’s first-half momentum in minerals and food testing translates to a stronger margin recovery. According to its investor page, the company will hold the briefing on May 18 at 10 a.m. AEST.
Tough timing, considering ALS stock has already seen a solid rally. Shares finished May 1 at A$21.36, nudging up 0.38% on the day. Over the past year, ALS has climbed 24.26%, moving within a 52-week band of A$15.97 to A$26.17.
Guidance will be key in the short run. Back in November, ALS bumped its FY26 organic revenue growth forecast up to 6%-8%, from a previous 5%-7%. The company also expects the FY26 profit split to look much like FY25’s, with roughly 48% of underlying net profit after tax booked in the first half and 52% in the back half. Worth noting: organic growth here refers to sales gains that leave out acquisitions, disposals, and currency swings.
The company’s first-half numbers were strong. Underlying revenue climbed 13.3% to A$1.66 billion. Underlying EBIT, which strips out interest and tax, jumped 14.7% to A$287.2 million. Margin on EBIT ticked up by 20 basis points, reaching 17.3%. For reference, a basis point equals one-hundredth of a percentage point.
“Strength in Commodities” carried the half, Chief Executive Malcolm Deane said, with Life Sciences still lagging. Chairman Nigel Garrard highlighted “resilient margins” as the board bumped up the interim dividend to 19.4 cents a share. ALS Global
ALS doesn’t fit the classic mining services mold. Reuters calls it a testing, measurement, and inspection company split between Commodities and Life Sciences. The Life Sciences business handles testing for environmental, food, pharma, electronics, consumer goods, and animal health industries.
This is what gives the May 18 update more heft than just the sample numbers. According to Morningstar, ALS’s move into environmental, pharmaceutical, and food testing has helped dial down its reliance on commodities for earnings—even if commodities still account for the bulk of its core profits.
Still, risks linger. ALS pointed to a softer-than-hoped Life Sciences showing for the first half. Environmental posted slower growth in the Americas, and a regulatory shift in Mexico weighed on Pharma. The company trimmed its FY26 organic growth outlook for Life Sciences to 4%-6%, down from 5%-7%, while bumping up the Commodities target to 12%-14%.
Competition isn’t going anywhere. ALS faces off with bigger players like SGS, Bureau Veritas, and Intertek in the testing, inspection, and certification (TIC) sector. Daniel Buerki of Zuercher Kantonalbank described the TIC market to Reuters last year as “not very consolidated.” Reuters
Scale is still a sticking point. Back in February, SGS signaled plans to keep hunting for deals in 2026, after snapping up 19 firms in 2025. ALS, for its part, said it’s eyeing bolt-on acquisitions in its main markets, sitting on over A$550 million in liquidity as of Sept. 30.
ALS investors will be watching May 18 for more than just a headline number. What matters: price, volume, and lab capacity need to keep moving in sync. If sample flows slow, Life Sciences loses steam again, or acquisition outlays can’t boost returns, convincing on margins gets tougher.
